Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 0.22
APNHF's Cash to Debt is ranked higher than
51% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. APNHF: 0.22 )
APNHF' s 10-Year Cash to Debt Range
Min: 0.22   Max: 128.44
Current: 0.22

0.22
128.44
Equity to Asset 0.35
APNHF's Equity to Asset is ranked higher than
52% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. APNHF: 0.35 )
APNHF' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.55
Current: 0.35

0.3
0.55
F-Score: 4
Z-Score: 2.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) 25.16
APNHF's Operating margin (%) is ranked higher than
93% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. APNHF: 25.16 )
APNHF' s 10-Year Operating margin (%) Range
Min: 25.16   Max: 28.07
Current: 25.16

25.16
28.07
Net-margin (%) 16.97
APNHF's Net-margin (%) is ranked higher than
90% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. APNHF: 16.97 )
APNHF' s 10-Year Net-margin (%) Range
Min: 14.38   Max: 20.91
Current: 16.97

14.38
20.91
ROE (%) 19.55
APNHF's ROE (%) is ranked higher than
93% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. APNHF: 19.55 )
APNHF' s 10-Year ROE (%) Range
Min: 17.51   Max: 45.46
Current: 19.55

17.51
45.46
ROA (%) 7.20
APNHF's ROA (%) is ranked higher than
84% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. APNHF: 7.20 )
APNHF' s 10-Year ROA (%) Range
Min: 7.83   Max: 18.83
Current: 7.2

7.83
18.83
ROC (Joel Greenblatt) (%) 48.34
APNHF's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. APNHF: 48.34 )
APNHF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 47.05   Max: 198.99
Current: 48.34

47.05
198.99
Revenue Growth (%) 33.40
APNHF's Revenue Growth (%) is ranked higher than
93% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. APNHF: 33.40 )
APNHF' s 10-Year Revenue Growth (%) Range
Min: 14.9   Max: 33.4
Current: 33.4

14.9
33.4
EBITDA Growth (%) 25.90
APNHF's EBITDA Growth (%) is ranked higher than
88% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. APNHF: 25.90 )
APNHF' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 37.9
Current: 25.9

0
37.9
EPS Growth (%) 32.00
APNHF's EPS Growth (%) is ranked higher than
89% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. APNHF: 32.00 )
APNHF' s 10-Year EPS Growth (%) Range
Min: 17.9   Max: 64.3
Current: 32

17.9
64.3
» APNHF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with APNHF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 36.20
APNHF's P/E(ttm) is ranked higher than
79% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. APNHF: 36.20 )
APNHF' s 10-Year P/E(ttm) Range
Min: 12.7   Max: 1215
Current: 36.2

12.7
1215
P/B 6.30
APNHF's P/B is ranked higher than
60% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. APNHF: 6.30 )
APNHF' s 10-Year P/B Range
Min: 2.65   Max: 13.83
Current: 6.3

2.65
13.83
P/S 6.20
APNHF's P/S is ranked higher than
65% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. APNHF: 6.20 )
APNHF' s 10-Year P/S Range
Min: 2.03   Max: 6.75
Current: 6.2

2.03
6.75
PFCF 100.40
APNHF's PFCF is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. APNHF: 100.40 )
APNHF' s 10-Year PFCF Range
Min: 17.18   Max: 340.22
Current: 100.4

17.18
340.22
EV-to-EBIT 26.81
APNHF's EV-to-EBIT is ranked higher than
80% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. APNHF: 26.81 )
APNHF' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 28
Current: 26.81

6.8
28
PEG 1.70
APNHF's PEG is ranked higher than
91% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. APNHF: 1.70 )
APNHF' s 10-Year PEG Range
Min: 0.48   Max: 3.08
Current: 1.7

0.48
3.08
Shiller P/E 58.90
APNHF's Shiller P/E is ranked higher than
80% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. APNHF: 58.90 )
APNHF' s 10-Year Shiller P/E Range
Min: 22.82   Max: 60.44
Current: 58.9

22.82
60.44
Current Ratio 1.95
APNHF's Current Ratio is ranked higher than
64% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. APNHF: 1.95 )
APNHF' s 10-Year Current Ratio Range
Min: 0.69   Max: 1.95
Current: 1.95

0.69
1.95
Quick Ratio 1.31
APNHF's Quick Ratio is ranked higher than
63% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. APNHF: 1.31 )
APNHF' s 10-Year Quick Ratio Range
Min: 0.48   Max: 1.31
Current: 1.31

0.48
1.31

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 6.77
APNHF's Price/DCF (Projected) is ranked higher than
78% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. APNHF: 6.77 )
APNHF' s 10-Year Price/DCF (Projected) Range
Min: 2.02   Max: 5.84
Current: 6.77

2.02
5.84
Price/Median PS Value 1.70
APNHF's Price/Median PS Value is ranked higher than
62% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. APNHF: 1.70 )
APNHF' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 1.48
Current: 1.7

0.41
1.48
Price/Peter Lynch Fair Value 1.70
APNHF's Price/Peter Lynch Fair Value is ranked higher than
93% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. APNHF: 1.70 )
APNHF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.54   Max: 2.45
Current: 1.7

0.54
2.45
Earnings Yield (Greenblatt) 3.70
APNHF's Earnings Yield (Greenblatt) is ranked higher than
80% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. APNHF: 3.70 )
APNHF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 14.8
Current: 3.7

3.6
14.8
Forward Rate of Return (Yacktman) 21.78
APNHF's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. APNHF: 21.78 )
APNHF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.3   Max: 32.9
Current: 21.78

1.3
32.9

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 3,499 4,232 4,912
EPS($) 1.31 1.71 2.09
EPS without NRI($) 1.31 1.71 2.09

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:LDZA.Germany, APN.South Africa,
Aspen Pharmacare Holdings Ltd is a pharmaceutical company. The Company, through its subsidiaries, is engaged in the manufacture, marketing and distribution of branded and generic pharmaceutical, as well as consumer, OTC and nutritional products in selected territories, operating primarily in the healthcare industry. Its product types includes tablets, capsules, eye drops, injectable products (including lyophilized vials), oral contraceptives, form-filled seals, suppositories, liquids, creams, ointments, infant nutritional products, and specialist active pharmaceutical ingredients. The Company operates in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, France, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America.
» More Articles for APNHF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK